Latest & greatest articles for ergocalciferol

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on ergocalciferol or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on ergocalciferol and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for ergocalciferol

1. Is there any evidence comparing the efficacy of ergocalciferol or cholecalciferol versus alfacacidol in correcting raised PTH in patients with stage 3 CKD?

Is there any evidence comparing the efficacy of ergocalciferol or cholecalciferol versus alfacacidol in correcting raised PTH in patients with stage 3 CKD? Is there any evidence comparing the efficacy of ergocalciferol or cholecalciferol versus alfacacidol in correcting raised PTH in patients with stage 3 CKD? - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document (...) ’ and this is something we aim to deliver for every single search. As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news. For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com Is there any evidence comparing the efficacy of ergocalciferol or cholecalciferol versus

2006 TRIP Answers

2. Ergocalciferol

Ergocalciferol Top results for ergocalciferol - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 (...) or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for ergocalciferol The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other

2018 Trip Latest and Greatest

3. Notice of Retraction: Sato Y, et al. The Prevention of Hip Fracture With Risedronate and Ergocalciferol Plus Calcium Supplementation in Elderly Women With Alzheimer Disease: A Randomized Controlled Trial. Arch Intern Med. 2005;165(15):1737-1742. (Abstract)

Notice of Retraction: Sato Y, et al. The Prevention of Hip Fracture With Risedronate and Ergocalciferol Plus Calcium Supplementation in Elderly Women With Alzheimer Disease: A Randomized Controlled Trial. Arch Intern Med. 2005;165(15):1737-1742. 27258431 2017 10 13 2168-6114 176 9 2016 09 01 JAMA internal medicine JAMA Intern Med Notice of Retraction: Sato Y, et al. The Prevention of Hip Fracture With Risedronate and Ergocalciferol Plus Calcium Supplementation in Elderly Women With Alzheimer

2016 JAMA Internal Medicine Controlled trial quality: uncertain

4. Plasma transport of ergocalciferol and cholecalciferol and their 25-hydroxylated metabolites in dairy cows. (Abstract)

Plasma transport of ergocalciferol and cholecalciferol and their 25-hydroxylated metabolites in dairy cows. In cattle, there are 2 significant forms of vitamin D: ergocalciferol (ERG) from fungi on roughage and cholecalciferol (CHO) from vitamin supplements or endogenous synthesis in the skin. The hypothesis of the present study is that vitamin D from the 3 sources is transported in different plasma fractions in the body. This is hypothesized to explain the lower efficiency of ERG compared

2017 Domestic animal endocrinology Controlled trial quality: uncertain

5. Treatment Effect of Ergocalciferol on Bone Metabolism Indexes and Parathyroid Hormone in Hemodialysis Patients. (Abstract)

Treatment Effect of Ergocalciferol on Bone Metabolism Indexes and Parathyroid Hormone in Hemodialysis Patients. Vitamin D deficiency is a common problem in end-stage renal disease patients under hemodialysis. Both active and nutritional vitamin D supplementation have been recommended for its treatment. In this study we aimed to evaluate the effects of treatment with ergocalciferol on bone metabolism indexes in hemodialysis patients.In a randomized controlled trial, 40 hemodialysis patients were (...) randomly allocated to the intervention (n = 20) and placebo (n = 20) groups. During the study, 4 patients in the placebo and 1 in the intervention group were excluded. Patients received calcitriol, 0.25 mg/d, with ergocalciferol, 50 000 IU, or placebo weekly for 3 months. Serum levels of 25-hydroxyvitamin D, calcium, parathyroid hormone, and alkaline phosphatase were measured before and after treatment.25-hydroxyvitamin D levels were significantly improved in the intervention group (12.00 ± 4.90 ng/mL

2018 Iranian journal of kidney diseases Controlled trial quality: uncertain

6. Determination of ergocalciferol in human plasma after Diels-Alder derivatization by LC–MS/MS and its application to a bioequivalence study Full Text available with Trip Pro

Determination of ergocalciferol in human plasma after Diels-Alder derivatization by LC–MS/MS and its application to a bioequivalence study An accurate, sensitive and selective method is developed for determination of ergocalciferol (vitamin D2) in human plasma using LC-MS/MS. After liquid-liquid extraction with n-hexane, ergocalciferol was derivatized by reacting with 4-phenyl-1,2,4-triazoline-3,5-dione (PTAD), a strong dienophile based on Diels-Alder reaction. Ergocalciferol and its (...) deuterated internal standard, ergocalciferol-d6, were analyzed on X Select CSH C18 (100 mm×4.6 mm, 2.5 µm) column using acetonitrile and 0.1% (v/v) formic acid in water containing 0.14% methylamine within 6.0 min under gradient elution mode. Tandem mass spectrometry in positive ionization mode was used to quantify ergocalciferol by multiple reaction monitoring (MRM). Entire data processing was done using Watson LIMS™ software which provided excellent data integrity and high throughput with improved

2017 Journal of Pharmaceutical Analysis

7. A randomized double-blinded placebo controlled trial of ergocalciferol 40,000 versus 100,000 IU per week for vitamin D inadequacy in institutionalized postmenopausal women. (Abstract)

A randomized double-blinded placebo controlled trial of ergocalciferol 40,000 versus 100,000 IU per week for vitamin D inadequacy in institutionalized postmenopausal women. Vitamin D inadequacy is common in institutionalized post-menopausal women who are at the highest risk for osteoporotic fracture.To evaluate efficacy and safety of ergocalciferol 40,000 versus 100,000 IU per week for 12 weeks for vitamin D inadequacy in institutionalized postmenopausal women.A randomized double-blinded (...) placebo-controlled trial was conducted in 94 institutionalized subjects with baseline 25(OH)D levels < 30 ng/mL. Subjects were randomized to receive ergocalciferol 40,000 (standard dose) or ergocalciferol 100,000 IU (high dose) per week. Serum 25(OH)D levels, calcium, phosphate, handgrip strength, time up and go (TUG) test and quality of life by EQ-5D-5L were measured at baseline and 12 weeks after randomization.Of the 94 subjects enrolled, 85 subjects completed the study. Subjects in the high dose

2019 Aging clinical and experimental research Controlled trial quality: predicted high

8. Pilot Study: The Effect of Ergocalciferol on Plasma Mucin-1 Levels

Pilot Study: The Effect of Ergocalciferol on Plasma Mucin-1 Levels Pilot Study: The Effect of Ergocalciferol on Plasma Mucin-1 Levels - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Pilot Study: The Effect (...) of Ergocalciferol on Plasma Mucin-1 Levels The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03747523 Recruitment Status : Not yet recruiting First Posted : November 20, 2018 Last Update Posted : February 15, 2019 See Sponsor: Wake

2018 Clinical Trials

9. Cholecalciferol v. ergocalciferol for 25-hydroxyvitamin D (25(OH)D) repletion in chronic kidney disease: a randomised clinical trial. Full Text available with Trip Pro

Cholecalciferol v. ergocalciferol for 25-hydroxyvitamin D (25(OH)D) repletion in chronic kidney disease: a randomised clinical trial. Patients with chronic kidney disease (CKD) demonstrate complex mineral metabolism derangements and a high prevalence of vitamin D deficiency. However, the optimal method of 25-hydroxyvitamin D (25(OH)D) repletion is unknown, and trials analysing the comparative efficacy of cholecalciferol and ergocalciferol in this population are lacking. We conducted (...) a randomised clinical trial of cholecalciferol 1250μg (50 000 IU) weekly v. ergocalciferol 1250μg (50 000 IU) weekly for 12 weeks in forty-four non-dialysis-dependent patients with stage 3-5 CKD. The primary outcome was change in total 25(OH)D from baseline to week 12 (immediately after therapy). Secondary analyses included the change in 1,25-dihydroxyvitamin D (1,25(OH)2D), parathyroid hormone (PTH), D2 and D3 sub-fractions of 25(OH)D and 1,25(OH)2D and total 25(OH)D from baseline to week 18 (6 weeks

2017 The British journal of nutrition Controlled trial quality: uncertain

10. Effect of Ergocalciferol on Iron Metabolism in Individuals With Chronic Kidney Disease

Effect of Ergocalciferol on Iron Metabolism in Individuals With Chronic Kidney Disease Effect of Ergocalciferol on Iron Metabolism in Individuals With Chronic Kidney Disease - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. Effect of Ergocalciferol on Iron Metabolism in Individuals With Chronic Kidney Disease The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03073369 Recruitment Status : Withdrawn (Study didn't materialize for various reasons.) First Posted : March 8, 2017 Last Update Posted : March 15

2017 Clinical Trials

11. Optimal Doses of Ergocalciferol Supplementation for Treatment of Hypovitaminosis D in Adults

Optimal Doses of Ergocalciferol Supplementation for Treatment of Hypovitaminosis D in Adults Optimal Doses of Ergocalciferol Supplementation for Treatment of Hypovitaminosis D in Adults - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more (...) studies before adding more. Optimal Doses of Ergocalciferol Supplementation for Treatment of Hypovitaminosis D in Adults The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03228862 Recruitment Status : Enrolling by invitation First Posted : July 25, 2017 Last Update Posted : July 26, 2017 Sponsor

2017 Clinical Trials

12. Efficacy Of Ergocalciferol In Adults According To BMI

Efficacy Of Ergocalciferol In Adults According To BMI Efficacy Of Ergocalciferol In Adults According To BMI - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Efficacy Of Ergocalciferol In Adults According (...) attributed to the increasing prevalence of obesity. Several studies have shown that obese patients have lower 25-OH vitamin D (25-OHD) levels compared to nonobese patients and obese patients require more vitamin D compared to nonobese patients. The most commonly prescribed medication to replete vitamin D deficiency is oral ergocalciferol. To date, no prospective trials have been published to evaluate a standard protocol in the treatment of vitamin D insufficiency in adults. Condition or disease

2013 Clinical Trials

13. A double-blind, randomized, placebo-controlled trial of combined calcitriol and ergocalciferol versus ergocalciferol alone in chronic kidney disease with proteinuria. Full Text available with Trip Pro

A double-blind, randomized, placebo-controlled trial of combined calcitriol and ergocalciferol versus ergocalciferol alone in chronic kidney disease with proteinuria. KDOQI guideline suggests that nutritional vitamin D should be supplemented in chronic kidney disease (CKD) patients who have vitamin D insufficiency/deficiency. However, there are scarce data regarding the additional benefit of active vitamin D supplement in CKD patients who were receiving nutritional vitamin D supplement (...) ergocalciferol plus placebo (n = 36) or oral ergocalciferol plus calcitriol (n = 32).The mean baseline values of UPCR of both groups were comparable (3.6 ± 3.8 g/g in combined group and 3.5 ± 3.0 g/g in ergocalciferol group). Following 12-week treatment, there were significant reductions in UPCR from baseline in both groups (2.3 ± 2.1 g/g in combined group and 2.4 ± 2.0 g/g in ergocalciferol group). The percentage reductions in UPCR of both groups were not significantly different. The mean eGFR and blood

2017 BMC Nephrology Controlled trial quality: predicted high

14. Vitamin D balance and distribution in rats given a massive dose of ergocalciferol: Part I. Experimental results Full Text available with Trip Pro

Vitamin D balance and distribution in rats given a massive dose of ergocalciferol: Part I. Experimental results 13058881 2003 05 01 2018 12 01 0264-6021 54 2 1953 May The Biochemical journal Biochem. J. Vitamin D balance and distribution in rats given a massive dose of ergocalciferol I. Experimental results. 337-43 CRUICKSHANK E M EM KODICEK E E eng Journal Article England Biochem J 2984726R 0264-6021 0 Ergocalciferols 0 Vitamins 1406-16-2 Vitamin D OM Animals Ergocalciferols Lipid Metabolism

1953 Biochemical Journal

15. Vitamin D balance and distribution in rats given a massive dose of ergocalciferol: Part II. Statistical analysis Full Text available with Trip Pro

Vitamin D balance and distribution in rats given a massive dose of ergocalciferol: Part II. Statistical analysis 13058882 2003 05 01 2018 12 01 0264-6021 54 2 1953 May The Biochemical journal Biochem. J. Vitamin D balance and distribution in rats given a massive dose of ergocalciferol. II. Statistical analysis. 344-7 ARMITAGE P P eng Journal Article England Biochem J 2984726R 0264-6021 0 Ergocalciferols 0 Vitamins 1406-16-2 Vitamin D OM Animals Ergocalciferols Lipid Metabolism Rats Vitamin D

1953 Biochemical Journal

16. The effect of ergosterol and ergocalciferol on the anaerobic glycolysis of rat-liver slices Full Text available with Trip Pro

The effect of ergosterol and ergocalciferol on the anaerobic glycolysis of rat-liver slices 14363154 2003 05 01 2018 12 01 0264-6021 59 4 1955 Apr The Biochemical journal Biochem. J. The effect of ergosterol and ergocalciferol on the anaerobic glycolysis of rat-liver slices. 605-9 FESTENSTEIN G N GN eng Journal Article England Biochem J 2984726R 0264-6021 0 Carbohydrates 0 Ergocalciferols 0 Vitamins 1406-16-2 Vitamin D Z30RAY509F Ergosterol OM Animals Carbohydrate Metabolism Carbohydrates (...) Ergocalciferols Ergosterol Glycolysis Liver metabolism Rats Vitamin D pharmacology Vitamins 5528:13988:115:332:609 CARBOHYDRATES/metabolism LIVER/metabolism VITAMIN D/effects 1955 4 1 1955 4 1 0 1 1955 4 1 0 0 ppublish 14363154 PMC1215625 Arch Biochem Biophys. 1953 May;44(1):150-8 13058363 Vitam Horm. 1953;11:29-60 13147056 J Biol Chem. 1951 Feb;188(2):471-6 14824134 Presse Med. 1951 Nov 7;59(70):1454-5 14891712 Biochem Z. 1952 Jan;322(4):245-62 14934713 Biochem J. 1952 Apr;51(1):1-9 14944524 Endocrinology

1955 Biochemical Journal

17. The vitamin D content of tissues of rats given ergocalciferol Full Text available with Trip Pro

The vitamin D content of tissues of rats given ergocalciferol 13198870 2003 05 01 2018 12 01 0264-6021 58 1 1954 Sep The Biochemical journal Biochem. J. The vitamin D content of tissues of rats given ergocalciferol. 172-5 CRUICKSHANK E M EM KODICEK E E ARMITAGE P P eng Journal Article England Biochem J 2984726R 0264-6021 0 Ergocalciferols 0 Vitamins 1406-16-2 Vitamin D OM Animals Ergocalciferols Rats Vitamin D analysis Vitamins 5527:10515:497 VITAMIN D/determination 1954 9 1 1954 9 1 0 1 1954 9

1954 Biochemical Journal

18. The stability of ergocalciferol in rodenticidal baits. Full Text available with Trip Pro

The stability of ergocalciferol in rodenticidal baits. Concentrations of the rodenticide ergocalciferol (vitamin D2) in samples of rodent baits laid in foodstores and in the laboratory were monitored over several months. Bait samples were solvent extracted and ergocalciferol concentration determined by high pressure liquid chromatography (HPLC). Ergocalciferol levels were constant for more than 21 days in dry samples and did not fall by more than 30% in 100 days. When water (10% w/w) was added (...) to the baits in the laboratory the ergocalciferol concentration fell by approximately 30% in 30 days. In these wet laboratory samples there was a rapid visible growth of fungus and in normal rodent control use baits should have been replaced when such deterioration became evident.

1983 The Journal of hygiene

19. Insulin secretion and sensitivity in healthy adults with low vitamin D are not affected by high-dose ergocalciferol administration: a randomized controlled trial. Full Text available with Trip Pro

Insulin secretion and sensitivity in healthy adults with low vitamin D are not affected by high-dose ergocalciferol administration: a randomized controlled trial. Epidemiologic data suggest that low serum 25-hydroxyvitamin D [25(OH)D] increases insulin resistance and the risk of type 2 diabetes. Few interventional trials have assessed the effect of vitamin D on insulin metabolism, and published results are discordant.The goal of this study was to perform a detailed assessment of the effect (...) of ergocalciferol administration on glucose and insulin metabolism in healthy people with low total 25(OH)D(total).This was a 12-wk, double-blinded, randomized controlled trial. We enrolled 90 healthy volunteers aged 18-45 y with serum 25(OH)D ≤20 ng/mL (by immunoassay) and administered 50,000 IU ergocalciferol/wk or placebo for 12 wk. Primary endpoints were change in first-phase insulin response and insulin sensitivity as measured by intravenous glucose tolerance test. Secondary endpoints included change

2015 The American journal of clinical nutrition Controlled trial quality: predicted high

20. Discrimination in the metabolism of orally dosed ergocalciferol and cholecalciferol by the pig, rat and chick. Full Text available with Trip Pro

Discrimination in the metabolism of orally dosed ergocalciferol and cholecalciferol by the pig, rat and chick. Vitamin D-deficient pigs, rats and chicks were repleted with four daily oral doses of crystalline ergocalciferol (vitamin D2) and cholecalciferol (vitamin D3) containing equal concentrations of each. At 24 h after the last dose, the plasma of each species was analysed for vitamin D and 25-hydroxyvitamin D by standard methods. The mean (+/- S.D.) ratios of plasma cholecalciferol (...) to ergocalciferol concentration were 1.5 +/- 0.1 (pig). 1.7 +/- 0.1 (rat) and 6.3 +/- 1.2 (chick). The mean ratios of plasma 25-hydroxycholecalciferol to 25-hydroxyergocalciferol concentration were 4.0 +/- 0.1 (pig), 0.4 +/- 0.02 (rat) and 10.7 +/- 3.4 (chick). The mean plasma cholecalciferol/ergocalciferol ratios for the 24,25-dihydroxy-, 25,26-dihydroxy- and 1,25-dihydroxy-derivatives in the pig were 2.6 +/- 0.6, 5.8 +/- 1.3 and 5.8 +/- 0.8 respectively. This is the first evidence that mammals other than

1982 Biochemical Journal